Breaking News

Oxford Biomedical Awarded NIH Grant

By Kristin Brooks | December 10, 2013

To develop proteomic toxicity screening panel

Oxford Biomedical Research, Inc. has been awarded a Phase II Small Business Innovation Research Grant by the National Institute of Environmental Health Sciences. The grant, valued at $1.2 million, is for the development of a panel of tests designed to use GST proteins as more sensitive and specific biomarkers to detect toxicity and differentiate potential toxic effects to multiple organs.
 
GST proteins, found in many tissues and organs, play an important role in the elimination of drugs and environmental compounds that humans are exposed to and are considered extremely sensitive biomarkers for toxicity.
 
Researchers at Oxford Biomedical Research have already assembled tests for a number of GST proteins. The NIH-funded research includes development of a device that can rapidly and inexpensively measure multiple GSTs. The utility of GSTs for organ-specific toxicity testing will be validated by comparison to conventional toxicity tests used during drug development and in the clinic.
  • Analytical Testing Outsourcing Trends Update

    Analytical Testing Outsourcing Trends Update

    January 26, 2017
    Spurred by many factors, global analytical testing services market is experiencing rapid growth in the range of 11% per year

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus